Ketamine and Psychedelics in PTSD and Depression: The New Frontier or the New Pandemic?
- 19 October 2023
- book chapter
- Published by Springer Nature
- p. 165-169
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Psilocybin in Treatment-Resistant DepressionNew England Journal of Medicine, 2022
- Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerabilityThe Lancet Psychiatry, 2022
- Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trialBMJ, 2022
- Models of psychedelic drug action: modulation of cortical-subcortical circuitsBrain, 2021
- Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSDJournal of Psychopharmacology, 2021
- Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network functionPharmacology & Therapeutics, 2019
- A Consensus Statement on the Use of Ketamine in the Treatment of Mood DisordersJAMA Psychiatry, 2017
- Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMAThe Lancet Psychiatry, 2016